By creating artificial aging in mice, researchers at Lund University in Sweden have been able to track the formation of ...

The Cardiac Centre at Al Qassimi Hospital, operated by Emirates Health Services (EHS), has become the first facility in the ...

Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...

The projection represents a negative annual growth rate of 0.08%. The total number of diagnosed prevalent cases of pulmonary ...

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy ...

ALG-801 is a novel next-generation ActRIIA/IIB hybrid ligand trap designed to selectively sequester a specific set of Smad2/3 pathway-activating ligands, which are critically involved in the ...

Primary pulmonary hypertension (PPH) is a progressive and usually fatal disease of unknown etiology 1–3 that leads to increased pulmonary vascular resistance and loss of the pulmonary vasodilator ...

Five other mutations – ALK1, ENG, SMAD9, CAV1 and KCNK3 – may also be in the foundations of idiopathic pulmonary hypertension pathophysiology. Note: Pulmonary Hypertension News is strictly a news and ...

8.Guazzi, M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. (2014) 7:367–77. doi: ...